KORU Medical Systems, Inc.
NASDAQ:KRMDMedical - Instruments & Supplies
+$0.06 today
- Market cap
- $149.64M
- Beta
- 0.42
- P/E (TTM)
- -80.2
- EPS (TTM)
- -$0.05
Volume 0.19M
Average 0.13M
KRMD EBITDA Margin
EBITDA as a percentage of revenue.
KORU Medical Systems, Inc.NASDAQ: KRMD
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -5.2%
EBITDA Margin was -5.2% in Q1 FY2026, up 4.7 pp from a year earlier. On a trailing-twelve-month basis it was -3.4%, up 9.6 pp year over year. Over 3 fiscal years it widened by 31.8 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 1.5% for the fiscal year ending Dec 2026, up from -4.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -5.2%-2.4 pp QoQ
- Last fiscal yearDec 2025
- -4.4%+11.3 pp YoY
- LTMMar 2026
- -3.4%+9.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +4.7 pp | -3.7 pp | -8.4 pp |
| 1 year | +11.3 pp | +5.8 pp | -5.5 pp |
| 3 years | +31.8 pp | +16.3 pp | -15.5 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -4.4%
- Year-over-year change
- +11.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -4.4% | +11.3pp |
| FY2024 | 2024-12-31 | -15.7% | +15.5pp |
| FY2023 | 2023-12-31 | -31.2% | +4.9pp |
| FY2022 | 2022-12-31 | -36.2% | -11.0pp |
| FY2021 | 2021-12-31 | -25.1% | — |
EBITDA Margin vs competitors
How KRMD compares with its peers on the latest reported figures
- KRMD's LTM Mar 2026 EBITDA Margin of -3.4% is the 3rd highest of the 10 companies compared; the peer median is -46.7%.
- Its year-over-year change of +9.6 pp is the 6th highest of 10, against a peer median of +22.3 pp.
- Over three fiscal years its change of +31.8 pp compares with a peer median of +30.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 43.6% | -2.2 pp | -8.8 pp | |
| LTM Mar 2026 | 18.2% | +2.6 pp | +4.0 pp | |
| LTM Mar 2026 | -3.4% | +9.6 pp | +31.8 pp | |
| LTM Mar 2026 | -17.0% | +26.6 pp | +30.8 pp | |
| LTM Mar 2026 | -45.4% | +91.4 pp | +1621.5 pp | |
| LTM Mar 2026 | -46.7% | +22.3 pp | +304.0 pp | |
| LTM Mar 2026 | -56.4% | -42.7 pp | -49.1 pp | |
| LTM Mar 2026 | -107.3% | -9.8 pp | -72.7 pp | |
| LTM Mar 2026 | -200.6% | +96.6 pp | +145.4 pp | |
| LTM Mar 2026 | -472.8% | +983.8 pp | +76.9 pp | |
| Peer median (excluding KRMD) | -46.7% | +22.3 pp | +30.8 pp | |
Competitors are the stored peer set for KRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 23.49M | 27.9M | 28.52M | 33.65M | 41.13M |
| Cost of Revenue | 9.72M | 12.53M | 11.81M | 12.31M | 15.52M |
| Gross Profit | 13.77M | 15.37M | 16.71M | 21.33M | 25.6M |
| Gross Margin | 58.6% | 55.1% | 58.6% | 63.4% | 62.3% |
| Research & Development | 2.47M | 4.96M | 5.74M | 5.26M | 4.39M |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 23.38M |
| Operating Expenses | 20.8M | 26.15M | 26.98M | 27.78M | 28.58M |
| Depreciation & Amortization | 463.13K | 587.14K | 870.39K | 772.89K | 810.5K |
| EBITDA | (5.9M) | (10.09M) | (8.9M) | (5.29M) | (1.81M) |
| EBITDA Margin | -25.1% | -36.2% | -31.2% | -15.7% | -4.4% |
| Operating Income | (7.03M) | (10.78M) | (10.27M) | (6.45M) | (2.97M) |
| Operating Margin | -29.9% | -38.6% | -36.0% | -19.2% | -7.2% |
| Interest Income | 13.08K | 145.59K | 561.33K | 444.64K | 293.4K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 665.09K | 105.71K | 496.4K | 382.49K | 356.41K |
| Income Before Tax | (6.36M) | (10.68M) | (9.77M) | (6.06M) | (2.62M) |
| Pre-Tax Margin | -27.1% | -38.3% | -34.3% | -18.0% | -6.4% |
| Income Tax Expense | (1.8M) | (2.01M) | 3.97M | 2.89K | 21.89K |
| Net Income | (4.56M) | (8.66M) | (13.74M) | (6.07M) | (2.64M) |
| Net Margin | -19.4% | -31.0% | -48.2% | -18.0% | -6.4% |
| EPS (Basic) | (0.10) | (0.19) | (0.30) | (0.13) | (0.06) |
| EPS (Diluted) | (0.10) | (0.19) | (0.30) | (0.13) | (0.06) |
| Weighted Avg Shares | 44.39M | 45M | 45.6M | 45.8M | 46.19M |
| Weighted Avg Shares (Diluted) | 44.39M | 45M | 45.6M | 45.8M | 46.19M |
KORU Medical Systems, Inc.
NASDAQ:KRMD
Intrinsic Alpha fair value
Locked
Current Price
$3.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.